The rate of obesity continues to be on the rise across all ages and demographics. While this is not a surprise to many, it is less well known the vast extent which weight management has been identified as first line treatment modalities for chronic diseases. The ACC/AHA guidelines have advocated for weight management as a means of controlling hypertension. Efforts to decrease rates of hepatocellular carcinoma have suggested that lifestyle modification can be the greatest step in preventing HHC and liver-related mortality. Even with this evidence and much more, patients continue to struggle with weight management. The Glucagon Like Peptide-1 (GLP-1) agonists have gained attention for their ability to promote significant weight reduction. But what is the mechanism to their impressive weight reduction ability, and what other clinical benefits may this class provide? This topic will discuss this and more.
Upon completion of this program, participants will be able to:
Statement of Accreditation
The Texas Osteopathic Medical Association (TOMA) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. TOMA designates is program for a maximum of 1 AOA Category 1-A credits and will report CME credits commensurate with the extent of the physician’s participation in this activity.
Grievance Policy
All grievances may be directed to TOMA's Executive Director at toma@txosteo.org. All grievances will receive an initial response within 30 days of receipt. If the participant does not receive a satisfactory response, they can submit a complaint to the Bureau of Osteopathic Education of the AOA at 142 East Ontario Street, Chicago, IL 60611.